Continuous Interscalene Blocks and Rebound Pain

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Calgary

About this trial

The primary objectives of this present study are to examine whether a continuous interscalene block of a total duration of 48 hours reduces the incidence of rebound pain comparatively to single-shot interscalene block, through the evaluation of the NRS scores at rest and on movement in the postoperative period at 24, 48, 72 and 96 hours as well as the total opioid consumption in the same timeframe for patients undergoing total shoulder arthroplasty.

Rebound pain has been defined in some studies as the "the transition from well-controlled pain (numerical rating scale \[NRS\] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance."

Eligibility criteria

Qualifiers

Adults aged >18 years of age

ASA I-III

Scheduled for elective ambulatory total shoulder arthroplasty.

Disqualifiers

ASA IV

Revision surgery

Contraindication to regional anesthesia (such as allergy to local anesthetics, systemic anticoagulation, local infection)

Preoperative chronic pain or opioid use

Trial design

Treatments tested in this trial

  • Continuous interscalene nerve block
  • Interscalene Block

Treatment groups

154 Participants
are divided into 2 treatment groups

Sponsors and collaborators